Retlirafusp alfa
As of the edition of 20 October 2026, Retlirafusp alfa is a protein: in active development; acts on CD274.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Protein
- Registered trials
- 62, 2 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Hormones; Skin and connective tissue; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | Q9NZQ7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 2 | 0 |
| Phase 1 | 5 | 1 | 1 | 0 |
| Phase 2 | 51 | 1 | 38 | 1 |
| Phase 3 | 4 | 0 | 2 | 1 |
| All trials | 62 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2018 to now |
| Atridia | Lead sponsor of trials | 2020 to now |